Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has announced the approval to begin clinical trials in China for LY03020, an innovative drug designed to treat schizophrenia and Alzheimer’s disease psychosis. This drug, created on the company’s New Chemical Entity/New Therapeutic Entity platform, is the world’s first to target both the TAAR1 and 5-HT2CR receptors, aiming to improve treatment for conditions affecting millions in China. Preclinical studies have shown LY03020 to significantly alleviate symptoms without the common side effects associated with current treatments.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
